A new formula for prostate cancer lymph node risk.
暂无分享,去创建一个
[1] A. D'Amico,et al. Predicting the risk of pelvic node involvement among men with prostate cancer in the contemporary era. , 2009, International journal of radiation oncology, biology, physics.
[2] A. D'Amico,et al. PSA velocity is associated with gleason score in radical prostatectomy specimen: marker for prostate cancer aggressiveness. , 2008, Urology.
[3] J. Moul,et al. Percent tumor involvement and risk of biochemical progression after radical prostatectomy. , 2008, The Journal of urology.
[4] M. Soloway,et al. Trends in Gleason score: concordance between biopsy and prostatectomy over 15 years. , 2008, Urology.
[5] A. D'Amico,et al. Targeting pelvic lymph nodes in men with intermediate- and high-risk prostate cancer despite two negative randomized trials. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] J. Epstein,et al. A contemporary study correlating prostate needle biopsy and radical prostatectomy Gleason score. , 2008, The Journal of urology.
[7] A. Haese*,et al. A nomogram is more accurate than a regression tree in predicting lymph node invasion in prostate cancer , 2008, BJU international.
[8] Charles R. Thomas,et al. An update of the phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: updated analysis of RTOG 94-13, with emphasis on unexpected hormone/radiation interactions. , 2007, International journal of radiation oncology, biology, physics.
[9] Y. Yoshioka,et al. Prostate Risk Index (PRIX) as a New Method of Risk Classification for Clinically Localized Prostate Cancer , 2007, Strahlentherapie und Onkologie.
[10] Alan W Partin,et al. Updated nomogram to predict pathologic stage of prostate cancer given prostate-specific antigen level, clinical stage, and biopsy Gleason score (Partin tables) based on cases from 2000 to 2005. , 2007, Urology.
[11] F. Montorsi,et al. Validation of a nomogram predicting the probability of lymph node invasion based on the extent of pelvic lymphadenectomy in patients with clinically localized prostate cancer , 2006, BJU international.
[12] Haiqun Lin,et al. Lymphovascular invasion is an independent prognostic factor in prostatic adenocarcinoma. , 2005, The Journal of urology.
[13] Yan Yan,et al. Relating biopsy and clinical variables to radical prostatectomy findings: can insignificant and advanced prostate cancer be predicted in a screening population? , 2004, Urology.
[14] Victor Reuter,et al. A preoperative nomogram identifying decreased risk of positive pelvic lymph nodes in patients with prostate cancer. , 2003, The Journal of urology.
[15] A. Heidenreich,et al. Extended pelvic lymphadenectomy in patients undergoing radical prostatectomy: high incidence of lymph node metastasis. , 2002, The Journal of urology.
[16] A. Partin,et al. Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience. , 2001, The Urologic clinics of North America.
[17] J. Epstein,et al. Gleason score 2-4 adenocarcinoma of the prostate on needle biopsy: a diagnosis that should not be made. , 2000, The American journal of surgical pathology.
[18] A. D'Amico,et al. Critical analysis of the ability of the endorectal coil magnetic resonance imaging scan to predict pathologic stage, margin status, and postoperative prostate-specific antigen failure in patients with clinically organ-confined prostate cancer. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] J. Oesterling,et al. Prostate specific antigen in the staging of localized prostate cancer: influence of tumor differentiation, tumor volume and benign hyperplasia. , 1990, The Journal of urology.
[20] E. Klein,et al. Limited pelvic lymph node dissection does not improve biochemical relapse-free survival at 10 years after radical prostatectomy in patients with low-risk prostate cancer. , 2008, Urology.
[21] J. Epstein,et al. Interobserver reproducibility of Gleason grading of prostatic carcinoma: general pathologist. , 2001, Human pathology.
[22] D. Bostwick,et al. Interobserver reproducibility of Gleason grading of prostatic carcinoma: urologic pathologists. , 2001, Human pathology.
[23] P. Carroll,et al. Predicting the risk of lymph node involvement using the pre-treatment prostate specific antigen and Gleason score in men with clinically localized prostate cancer. , 1994, International journal of radiation oncology, biology, physics.